Objectives:

1. The learner will understand the pathophysiological rationale for complement inhibitor therapy for myasthenia gravis
2. The learner will be able to determine appropriate application of complement inhibitor therapy for myasthenia gravis patients; and
3. The learner will become familiar with the next generation of complement inhibitors under development.

Session date: 
Thursday, May 16, 2019 - 7:30am to 8:30am
Speaker Name: 
Henry Kaminski MD
Location: 
UCMC
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.